feed,title,long_url,short_url
Benzinga,Lundbeck Out Licenses Flopped Alzheimer's Drug In Wake Of Biogen's Controversial Success With Aducanumab,https://benzinga.com/general/biotech/21/07/21828358/lundbeck-out-licenses-flopped-alzheimers-drug-in-wake-of-biogens-controversial-success-with-aduca,https://j.mp/3qFrPQe
Benzinga,GlaxoSmithKline's Board Backs CEO Walmsley After Elliott's Letter For Management Shakeup,https://benzinga.com/general/biotech/21/07/21827823/glaxosmithklines-board-backs-ceo-walmsley-after-elliotts-letter-for-management-shakeup,https://j.mp/3jyE7Zb
